Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments

Susanne Vrtala, Kora Hirtenlehner, Luca Vangelista, Annalisa Pastore, Hans Georg Eichler, Wolfgang R. Sperr, Peter Valent, Christof Ebner, Dietrich Kraft, Rudolf Valenta

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We have expressed in Escherichia coli two halves of the major birch pollen allergen, Bet v 1. Both fragments representing the complete 17-kD allergen were purified to homogeneity. In contrast to the complete recombinant, Bet v 1, the fragments had almost completely lost their IgE-binding capacity and exhibited a random coil structure as analyzed by circular dichroism. The ability of the recombinant fragments to trigger histamine release from allergic patients' basophils as well as their capacity to elicit skin reactions were also largely abolished. Both non-anaphylactic Bet v 1 fragments carried the majority of T cell epitopes and may therefore be considered as safe tools for immunotherapy of tree pollen and associated food allergy.

Original languageEnglish
Pages (from-to)246-248
Number of pages3
JournalInternational Archives of Allergy and Immunology
Volume113
Issue number1-3
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Betula
Pollen
Allergens
T-Lymphocyte Epitopes
Food Hypersensitivity
Basophils
Histamine Release
Circular Dichroism
Immunotherapy
Immunoglobulin E
Escherichia coli
Skin

Keywords

  • IgE
  • Immunotherapy
  • Recombinant birch pollen allergen (Bet v 1)
  • Skin testing
  • T cell vaccine
  • Type I allergy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Vrtala, S., Hirtenlehner, K., Vangelista, L., Pastore, A., Eichler, H. G., Sperr, W. R., ... Valenta, R. (1997). Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments. International Archives of Allergy and Immunology, 113(1-3), 246-248.

Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments. / Vrtala, Susanne; Hirtenlehner, Kora; Vangelista, Luca; Pastore, Annalisa; Eichler, Hans Georg; Sperr, Wolfgang R.; Valent, Peter; Ebner, Christof; Kraft, Dietrich; Valenta, Rudolf.

In: International Archives of Allergy and Immunology, Vol. 113, No. 1-3, 1997, p. 246-248.

Research output: Contribution to journalArticle

Vrtala, S, Hirtenlehner, K, Vangelista, L, Pastore, A, Eichler, HG, Sperr, WR, Valent, P, Ebner, C, Kraft, D & Valenta, R 1997, 'Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments', International Archives of Allergy and Immunology, vol. 113, no. 1-3, pp. 246-248.
Vrtala, Susanne ; Hirtenlehner, Kora ; Vangelista, Luca ; Pastore, Annalisa ; Eichler, Hans Georg ; Sperr, Wolfgang R. ; Valent, Peter ; Ebner, Christof ; Kraft, Dietrich ; Valenta, Rudolf. / Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments. In: International Archives of Allergy and Immunology. 1997 ; Vol. 113, No. 1-3. pp. 246-248.
@article{f9ea291b02ee466ab3c2cce659f79f06,
title = "Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments",
abstract = "We have expressed in Escherichia coli two halves of the major birch pollen allergen, Bet v 1. Both fragments representing the complete 17-kD allergen were purified to homogeneity. In contrast to the complete recombinant, Bet v 1, the fragments had almost completely lost their IgE-binding capacity and exhibited a random coil structure as analyzed by circular dichroism. The ability of the recombinant fragments to trigger histamine release from allergic patients' basophils as well as their capacity to elicit skin reactions were also largely abolished. Both non-anaphylactic Bet v 1 fragments carried the majority of T cell epitopes and may therefore be considered as safe tools for immunotherapy of tree pollen and associated food allergy.",
keywords = "IgE, Immunotherapy, Recombinant birch pollen allergen (Bet v 1), Skin testing, T cell vaccine, Type I allergy",
author = "Susanne Vrtala and Kora Hirtenlehner and Luca Vangelista and Annalisa Pastore and Eichler, {Hans Georg} and Sperr, {Wolfgang R.} and Peter Valent and Christof Ebner and Dietrich Kraft and Rudolf Valenta",
year = "1997",
language = "English",
volume = "113",
pages = "246--248",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "1-3",

}

TY - JOUR

T1 - Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments

AU - Vrtala, Susanne

AU - Hirtenlehner, Kora

AU - Vangelista, Luca

AU - Pastore, Annalisa

AU - Eichler, Hans Georg

AU - Sperr, Wolfgang R.

AU - Valent, Peter

AU - Ebner, Christof

AU - Kraft, Dietrich

AU - Valenta, Rudolf

PY - 1997

Y1 - 1997

N2 - We have expressed in Escherichia coli two halves of the major birch pollen allergen, Bet v 1. Both fragments representing the complete 17-kD allergen were purified to homogeneity. In contrast to the complete recombinant, Bet v 1, the fragments had almost completely lost their IgE-binding capacity and exhibited a random coil structure as analyzed by circular dichroism. The ability of the recombinant fragments to trigger histamine release from allergic patients' basophils as well as their capacity to elicit skin reactions were also largely abolished. Both non-anaphylactic Bet v 1 fragments carried the majority of T cell epitopes and may therefore be considered as safe tools for immunotherapy of tree pollen and associated food allergy.

AB - We have expressed in Escherichia coli two halves of the major birch pollen allergen, Bet v 1. Both fragments representing the complete 17-kD allergen were purified to homogeneity. In contrast to the complete recombinant, Bet v 1, the fragments had almost completely lost their IgE-binding capacity and exhibited a random coil structure as analyzed by circular dichroism. The ability of the recombinant fragments to trigger histamine release from allergic patients' basophils as well as their capacity to elicit skin reactions were also largely abolished. Both non-anaphylactic Bet v 1 fragments carried the majority of T cell epitopes and may therefore be considered as safe tools for immunotherapy of tree pollen and associated food allergy.

KW - IgE

KW - Immunotherapy

KW - Recombinant birch pollen allergen (Bet v 1)

KW - Skin testing

KW - T cell vaccine

KW - Type I allergy

UR - http://www.scopus.com/inward/record.url?scp=8244240425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8244240425&partnerID=8YFLogxK

M3 - Article

VL - 113

SP - 246

EP - 248

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 1-3

ER -